SuperworthPROCEPT BioRobotics EPS PRCT
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$1.94
- Latest quarter, Q2 FY26
- −$0.47
- Fiscal year 2025
- −$1.71
PROCEPT BioRobotics' earnings per share was −$1.94 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.47.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.71 | n/a |
| FY2024 | −$1.76 | n/a |
| FY2023 | −$2.24 | n/a |
| FY2022 | −$1.96 | n/a |
| FY2021 | −$6.89 | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.47 | n/a | −$1.94 | |
| Q1 FY26 | −$0.56 | n/a | −$1.82 | |
| Q4 FY25 | −$0.53 | n/a | −$1.71 | |
| Q3 FY25 | −$0.38 | n/a | −$1.53 | |
| Q2 FY25 | −$0.35 | n/a | −$1.55 | |
| Q1 FY25 | −$0.45 | n/a | −$1.70 | |
| Q4 FY24 | −$0.35 | n/a | −$1.76 | |
| Q3 FY24 | −$0.40 | n/a | −$1.95 | |
| Q2 FY24 | −$0.50 | n/a | −$2.06 | |
| Q1 FY24 | −$0.51 | n/a | −$2.12 | |
| Q4 FY23 | −$0.54 | n/a | −$2.24 | |
| Q3 FY23 | −$0.51 | n/a | −$2.33 |
Against its peers
Companies in Medical - Instruments & Supplies nearest PROCEPT BioRobotics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PRCTPROCEPT BioRobotics | −$1.94 | |
| STAAStaar Surgical | $0.07 | |
| IRMDIradimed | $1.79 | +10% a year |
| BVSBioventus | $0.77 | |
| CDRECadre | $0.81 | −14% a year |
| EYENational Vision | $0.61 | |
| MOVMovado | $1.80 | +137% a year |
| LMATLemaitre Vascular | $2.85 | +38% a year |
| INSPInspire Medical Systems | $4.62 | +166% a year |
| UFPTUFP Technologies | $9.28 | +8% a year |
| MDXGMimedx | $0.04 | −81% a year |
| Peer median | $1.30 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on PROCEPT BioRobotics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.